Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Inozyme Pharma (NASDAQ:INZY) and maintained a $23 price target.
August 06, 2024 | 5:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a Buy rating on Inozyme Pharma (NASDAQ:INZY) and maintained a $23 price target.
The reiteration of a Buy rating and the maintenance of a $23 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100